カテゴリ： Grand View Research, 世界, 医療/バイオ

メラノーマ治療薬のグローバル市場（2023～2030）：化学療法、免疫療法

■ 英語タイトル：Melanoma Therapeutics Market Size, Share & Trends Analysis Report By Product (Chemotherapy, Immunotherapy), By Drug Type (Branded Drugs, Generic Drugs), By Region, And Segment Forecasts, 2023 - 2030

調査会社Grand View Research社が発行したリサーチレポート（データ管理コード：GRV23NOV209）■ 発行会社/調査会社：Grand View Research
■ 商品コード：GRV23NOV209
■ 発行日：2023年9月
■ 調査対象地域：グローバル
■ 産業分野：医療機器
■ ページ数：100
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後3営業日）
■ 販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[メラノーマ治療薬のグローバル市場（2023～2030）：化学療法、免疫療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

メラノーマ治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、メラノーマ治療薬の世界市場規模は2030年までに109億8000万米ドルに達し、2023年から2030年までの年平均成長率は10.3％を記録すると予測されています。メラノーマ、皮膚癌、皮膚アレルギーなどの慢性疾患の罹患率の増加は、市場の重要な促進要因です。

CDCによると、2013年には71,943人以上がメラノーマに罹患しました。米国癌協会は、この数が2017年には87,100人に増加すると推定しており、予測期間中のメラノーマ治療薬の必要性を強調しています。

FDAの承認数の増加や、有効性を高めた新規治療薬の登場も成長機会をもたらすと予測されています。2011年から2016年までの6年間に、オプジーボ、ヤーボイ、コテリック、ゼルボラフ、キイトルーダ、メキニスト、タフィンラー、イムリジックの8つの生物学的製剤がこの疾患の治療薬として承認されました。

各社は、既存製品の新たな適応症の発見や革新的な分子の開発に向けて、さまざまな研究開発活動を行っています。例えば、2014年9月、米国FDAは転移性黒色腫の治療薬として特許薬キイトルーダ（Merck & Co., Inc.）が非小細胞肺がんの治療薬として承認されていました。

さらに、米国、欧州、アジア太平洋地域の多くの製薬企業が、新たな生物学的製剤の開発に注力しています。例えば、第一三共株式会社は2017年3月、共同研究による新薬開発を促進するための共同創薬プロジェクト「Take a New Challenge for Drug discovery（TaNeDS）」を発表しました。また、AgonOX, Inc.と戦略的研究提携を締結し、免疫・がん領域における新規免疫療法薬の開発を進めています。予測期間中に新規製品が承認されれば、市場の成長が促進されると予想されます。

メラノーマ治療薬市場レポートハイライト

- 標的療法分野は、副作用の少なさや効率の高さなどの利点により、予測期間中に11.9%の有利な成長が予測されます。

- 特許による独占権により、2022年の業界シェアはブランド薬が91.33%と圧倒的です。

- オプジーボやコテリックなどの生物学的製剤は、採用の増加や治療効果の向上などの利点により、予測期間中に有利な成長を示す見込みです。

- ヤーボイの特許は米国では2022年、欧州では2020年に失効されました。これにより、新規参入企業に成長機会がもたらされる見込みです。

- アジア太平洋地域は予測期間中に11.6%の有利なCAGRを示す見込みです。

- 主要企業はメラノーマ治療のための新薬の発見と開発のための研究開発努力を強化しています。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界のメラノーマ治療薬市場：製品別予測・動向分析
第5章. 世界のメラノーマ治療薬市場：薬剤タイプ別予測・動向分析
第6章. 世界のメラノーマ治療薬市場：地域別予測・動向分析
第7章. 競争状況

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis
4.1. Melanoma Therapeutics Market: Key Takeaways
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis
5.1. Melanoma Therapeutics Market: Key Takeaways
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives=

List of Tables

Table 1 List of Abbreviation
Table 2 North America melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 3 North America melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 4 North America melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 5 U.S. melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 6 U.S. melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 7 Canada melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 8 Canada melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 9 Europe melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 10 Europe melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 11 Europe melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 12 Germany melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 13 Germany melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 14 UK melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 15 UK melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 16 France melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 17 France melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 18 Italy melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 19 Italy melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 20 Spain melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 21 Spain melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 22 Sweden melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 23 Sweden melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 24 Norway melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 25 Norway melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 26 Denmark melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 27 Denmark melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 31 China melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 32 China melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 33 Japan melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 34 Japan melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 35 India melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 36 India melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 37 Thailand melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 38 Thailand melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 39 South Korea melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 40 South Korea melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 41 Latin America melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 42 Latin America melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 43 Latin America melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 44 Brazil melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 45 Brazil melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 46 Mexico melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 47 Mexico melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 48 Argentina melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 49 Argentina melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 – 2030 (USD Million)
Table 53 South Africa melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 54 South Africa melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 57 UAE melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 58 UAE melanoma therapeutics market, by drug type, 2018 – 2030 (USD Million)
Table 59 Kuwait melanoma therapeutics market, by product, 2018 – 2030 (USD Million)
Table 60 Kuwait melanoma therapeutics market, by drug type, (USD Million) 2018 – 2030Report SummaryTable of ContentsSegmentationMethodologyRequest a FREE Sample Copy
Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug type
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug type outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.2. Market restraints analysis
3.4. Melanoma Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis
4.1. Melanoma Therapeutics Market: Key Takeaways
4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Radiation Therapy
4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis
5.1. Melanoma Therapeutics Market: Key Takeaways
5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Branded Drugs
5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Generic Drugs
5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Melanoma Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Bristol-Myers Squibb Company
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. AstraZeneca
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Merck & Co, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Amgen Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. F. Hoffman-La Roche Ltd.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Abbott Laboratories.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 大腸がん治療薬のグローバル市場2023-2030：化学療法、免疫療法
  • 世界の肝臓転移治療市場2023-2030：化学療法、標的療法、免疫療法
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GRV23NOV209 )"メラノーマ治療薬のグローバル市場（2023～2030）：化学療法、免疫療法" (英文：Melanoma Therapeutics Market Size, Share & Trends Analysis Report By Product (Chemotherapy, Immunotherapy), By Drug Type (Branded Drugs, Generic Drugs), By Region, And Segment Forecasts, 2023 - 2030)はGrand View Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。